1. Home
  2. SRCE vs MLYS Comparison

SRCE vs MLYS Comparison

Compare SRCE & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 1st Source Corporation

SRCE

1st Source Corporation

HOLD

Current Price

$80.42

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$30.42

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRCE
MLYS
Founded
1863
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
SRCE
MLYS
Price
$80.42
$30.42
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
$74.50
$48.67
AVG Volume (30 Days)
139.0K
1.8M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
2.37%
N/A
EPS Growth
19.59
37.43
EPS
1.63
N/A
Revenue
N/A
N/A
Revenue This Year
$10.29
N/A
Revenue Next Year
$3.16
N/A
P/E Ratio
$50.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.89
$12.59
52 Week High
$83.90
$47.65

Technical Indicators

Market Signals
Indicator
SRCE
MLYS
Relative Strength Index (RSI) 56.94 68.52
Support Level $71.36 $25.88
Resistance Level $83.90 $31.29
Average True Range (ATR) 1.97 1.43
MACD -0.03 0.66
Stochastic Oscillator 55.92 87.59

Price Performance

Historical Comparison
SRCE
MLYS

About SRCE 1st Source Corporation

1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: